Calibration verification/linearity test kits, 9/16
September 2016—LGC Maine Standards released its Validate Tumor Markers and Validate Whole Blood Glucose calibration verification/linearity test kits.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2016—LGC Maine Standards released its Validate Tumor Markers and Validate Whole Blood Glucose calibration verification/linearity test kits.
September 2016—Streck and Biodesix, a molecular diagnostics company that develops blood-based tests in oncology, have signed an agreement to make Streck the exclusive supplier of DNA and RNA tubes for Biodesix.
August 2016—Myriad Genetics announced that its myChoice HRD test successfully identified an increased number of patients with ovarian cancer who may benefit from treatment with niraparib, an investigational oral PARP inhibitor being developed by Tesaro. The announcement follows results of the NOVA study, which evaluated the safety and efficacy of niraparib as a maintenance therapy in more than 500 patients with recurrent ovarian cancer.
August 2016—Streck’s Cell-Free DNA BCT, for the collection and preservation of whole blood samples, is available as a 2.0 mL draw tube. The formaldehyde-free preservative reagent contained in Cell-Free DNA BCT inhibits nuclease-mediated degradation of cf-DNA and stabilizes nucleated blood cells, which prevents the release of cellular genomic DNA. Samples are stable for up to 14 days at temperatures between 6°–37°C, allowing convenient sample collection, transport, and storage.
August 2016—Biocept launched its CLIA-validated PD-L1 protein expression test, which uses Biocept’s proprietary, patented Target Selector platform with circulating tumor cells from a patient’s blood sample and can be used to detect and monitor PD-L1 protein expression throughout the course of a patient’s cancer therapy.
August 2016—Boekel Scientific introduced its RapidFISH slide hybridizer designed to simplify fluorescence in situ hybridization procedures for formalin-fixed, paraffin-embedded tissue samples, cell suspensions, and other tissue preparation procedures. The RapidFISH has a self-clamping slide tray design that maintains the required humidity and has an easy-to-use control system for temperature, time, and controlled temperature steps.
August 2016—The Olympus BX46 microscope’s specially designed ergonomic features aim to provide enhanced operator comfort during long hours of use.
August 2016—Safety-Spec, a pathologist-owned company, has announced that the Gross Room Lab Tray is available for order on its website, Safety-Spec.com. Designed by a pathologist and laboratory scientist, the tray provides improved specimen organization in the gross room queue, resulting in increased efficiency and patient safety by reducing the potential for misidentification of specimens from a patient (intra-accession mislabeling) as well as misidentification between patients (inter-accession mislabeling).
August 2016—A study published in Oncotarget (Brachtel EF, et al. Epub ahead of print March 28, 2016) demonstrates the high accuracy and success rate of Biotheranostics’ CancerType ID molecular cancer classifier in the diagnosis of cancer for specimens with limited tissue. Results from the study support additional clinical utility for CancerType ID in small biopsy and cytology cases.
August 2016—LGC Maine Standards announced its Validate D-Dimer calibration verification/linearity test kit has received 510(k) clearance for use on Instrumentation Laboratory’s ACL TOP hemostasis test systems. The kit evaluates D-dimer in a human-plasma base matrix, is prepared using the CLSI recommended “equal delta” method for linearity testing, and is liquid, ready to use.